Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NextCure Inc.

www.nextcure.com

Latest From NextCure Inc.

Start-Up Quarterly Statistics: Relay, Cerevel Financings Lead Q4 VC Deals

A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.

Deals Financing

NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition

Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.

StartUps and SMEs ImmunoOncology

Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services

Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.

Financing StartUps and SMEs

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • NextCure Inc.
  • Senior Management
  • Michael Richman, Pres. & CEO
    Steven P Cobourn, CFO
    Solomon Langermann, PhD, SVP, Research
    Kevin H Heller, MD, CMO
    Timothy Mayer, PhD, VP, Bus. Dev.
  • Contact Info
  • NextCure Inc.
    Phone: (240) 399-4900
    9000 Virginia Manor Rd.
    Ste. 200
    Beltsville, MD 20705
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register